Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction

Abstract

Objective: To compare the effects of an angiotensin receptor blocker(ARB)-based regimen versus a non-ARB based regimen on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. Methods: 97 patients with a systolic blood pressure (SBP) ≥140 mmHg, a left ventricular ejection fraction >0.50, and echocardiographic evidence of diastolic dysfunction were randomly assignment to open-label treatment with eprosartan (with other anti-hypertensives; n=47) or other anti-hypertensives alone (n=50). Echocardiography, including tissue Doppler imaging (TDI), and neurohormones were done at baseline and after 6 months. Results: Mean age was 65 (±10) years and 64% was female. During 6 months of treatment, SBP decreased from 157±16 to 145±18 mmHg in the eprosartan group and from 158±17 to 141±18 mmHg in the control group (both p<0.001; p = ns between groups). Diastolic function was unaffected in both groups and there was no correlation between changes in SBP and changes in mean TDI (r=-0.06; p=0.58). Aldosterone levels decreased in the eprosartan group, but other neurohormones remained largely unchanged. Change in SBP was however related to the change in NT-proBNP (r=0.26; p=0.019). Conclusion: Lowering blood pressure, either with eprosartan or other anti-hypertensives in hypertensive patients with diastolic dysfunction did not change diastolic function after 6 months of treatment, but was associated with a decrease of NT-proBNP. © 2010 The Author(s).